line
Japanese Society for Palliative Medicine
News Letter No.90
日本緩和医療学会ニューズレター
Feb 2021  90
Journal Watch
緩和ケアに関する論文レビュー
名古屋大学大学院 医学系研究科 総合保健学専攻高度実践看護開発学講座
佐藤 一樹

対象雑誌:N Engl J Med, Lancet, Lancet Oncol, JAMA, JAMA Intern Med, JAMA Oncol, BMJ, Ann Intern Med, J Clin Oncol, Ann Oncol, Eur J Cancer, Br J Cancer, Cancer

対象期間:2020年9月〜2020年11月刊行分

いわゆる“トップジャーナル”に掲載された緩和ケアに関する最新論文を広く紹介します。


【N Engl J Med. 2020;383(10-22)】
なし

【Lancet. 2020;396(10251-10263)】
1. 慢性骨盤痛に対するガバペンチンの無作為化比較試験
Horne AW, Vincent K, Hewitt CA, Middleton LJ, Koscielniak M, Szubert W, et al. Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2020;396(10255):909-17.[PMID: 32979978]

【Lancet Oncol.2020;21(9-11)】
なし

【JAMA. 2020;324(9-20)】
2. 非がん患者での緩和ケア介入と医療資源利用・QOL・症状の関連:システマティックレビュー
Quinn KL, Shurrab M, Gitau K, Kavalieratos D, Isenberg SR, Stall NM, et al. Association of Receipt of Palliative Care Interventions With Health Care Use, Quality of Life, and Symptom Burden Among Adults With Chronic Noncancer Illness: A Systematic Review and Meta-analysis. JAMA. 2020;324(14):1439-50. [PMID: 33048152]

【JAMA Intern Med. 2020;6(9-11)】
3. ナーシングホーム長期居住高齢者に対するACPのビデオ介入のクラスター無作為化試験
Mitchell SL, Volandes AE, Gutman R, Gozalo PL, Ogarek JA, Loomer L, et al. Advance Care Planning Video Intervention Among Long-Stay Nursing Home Residents: A Pragmatic Cluster Randomized Clinical Trial. JAMA Intern Med. 2020;180(8):1070-8. [PMID: 32628258]
4. 慢性関節痛に対するNSAIDsと認知行動療法の無作為化比較試験
Fraenkel L, Buta E, Suter L, Dubreuil M, Levy C, Najem C, et al. Nonsteroidal Anti-inflammatory Drugs vs Cognitive Behavioral Therapy for Arthritis Pain: A Randomized Withdrawal Trial. JAMA Intern Med. 2020;180(9):1194-202. [PMID: 32702101]
5. 慢性心不全患者に対する遠隔的な早期緩和ケア介入の無作為化比較試験:ENABLE CHF-PC試験
Bakitas MA, Dionne-Odom JN, Ejem DB, Wells R, Azuero A, Stockdill ML, et al. Effect of an Early Palliative Care Telehealth Intervention vs Usual Care on Patients With Heart Failure: The ENABLE CHF-PC Randomized Clinical Trial. JAMA Intern Med. 2020;180(9):1203-13. [PMID: 32730613]
6. COPD患者の耐え難い息切れに対する経口徐放モルヒネの無作為化比較試験
Verberkt CA, van den Beuken-van Everdingen MHJ, Schols J, Hameleers N, Wouters EFM, Janssen DJA. Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial. JAMA Intern Med. 2020;180(10):1306-14. [PMID: 32804188]

【JAMA Oncol. 2020;180(9-11)】
7. 小児がん長期サバイバーの聴覚障害と神経認知機能との関連
Bass JK, Liu W, Banerjee P, Brinkman TM, Mulrooney DA, Gajjar A, et al. Association of Hearing Impairment With Neurocognition in Survivors of Childhood Cancer. JAMA Oncol. 2020;6(9):1363-71. [PMID: 32729886]
8. 進行あるいは転移性大腸がん患者 のコーヒー摂取量と予後との関連
Mackintosh C, Yuan C, Ou FS, Zhang S, Niedzwiecki D, Chang IW, et al. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020. [PMID: 32940631]
9. 機械学習アルゴリズムによる外来がん患者の180日死亡リスク予測モデルの妥当性
Manz CR, Chen J, Liu M, Chivers C, Regli SH, Braun J, et al. Validation of a Machine Learning Algorithm to Predict 180-Day Mortality for Outpatients With Cancer. JAMA Oncol. 2020. [PMID: 32970131]
10. 前立腺がん患者の臨床試験の希望の人種間比較(Brief Report)
Senft N, Hamel LM, Manning MA, Kim S, Penner LA, Moore TF, et al. Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer. JAMA Oncol. 2020. [PMID: 32940630]

【BMJ. 2020;370(8258-8261), 371(62-8270)】
11. がん治療開始の遅れと予後の関連:システマティックレビューとメタ分析
Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087. [PMID: 33148535]

【Ann Intern Med. 2020;174(5-10)】
12. 経口ステロイドバーストによる重度な有害事象
Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study. Ann Intern Med. 2020;173(5):325-30. [PMID: 32628532]
13. 出産後のオピオイド処方と重篤な有害事象のリスク:メタ分析
Osmundson SS, Min JY, Wiese AD, Hawley RE, Mitchel E, Patrick SW, et al. Opioid Prescribing After Childbirth and Risk for Serious Opioid-Related Events: A Cohort Study. Ann Intern Med. 2020;173(5):412-4.[PMID: 32510992]
14. 米国食品医薬品局FDAで承認されたオピオイド鎮痛薬の1997〜2018年の主なエビデンス
Heyward J, Moore TJ, Chen J, Meek K, Lurie P, Alexander GC. Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018. Ann Intern Med. 2020;173(12):956-63. [PMID: 32986486]

【J Clin Oncol. 2020;38(25-33)】
15. 薬物関連顎骨壊死:MASCC / ISOO / ASCO 臨床診療ガイドライン
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270-90. [PMID: 31329513]
16. 小児白血病治療後の感染の長期的リスク
Pelland-Marcotte MC, Pole JD, Hwee J, Sutradhar R, Science M, Nathan PC, et al. Long-Term Risk of Infections After Treatment of Childhood Leukemia: A Population-Based Cohort Study Using Administrative Health Data. J Clin Oncol. 2019;37(29):2651-60. [PMID: 31393747]
17. インフルエンザワクチンのがん患者での有効性
Blanchette PS, Chung H, Pritchard KI, Earle CC, Campitelli MA, Buchan SA, et al. Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada. J Clin Oncol. 2019;37(30):2795-804. [PMID: 31465264]
18. がん再発恐怖に対する心理介入の効果:システマティックレビューとメタ分析
Tauber NM, O'Toole MS, Dinkel A, Galica J, Humphris G, Lebel S, et al. Effect of Psychological Intervention on Fear of Cancer Recurrence: A Systematic Review and Meta-Analysis. J Clin Oncol. 2019;37(31):2899-915. [PMID: 31532725]
19. 非転移性がん患者の骨粗鬆症マネジメント:ASCO臨床診療ガイドライン
Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(31):2916-46. [PMID: 31532726]

【Ann Oncol. 2020;31(9-11)】
20. 化学療法誘発性末梢神経障害の診断・予防・治療・経過観察:ESMO-EONS-EANO臨床診療ガイドライン(Special Articles)
Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31(10):1306-19.[PMID: 32739407]
21. Covid-19パンデミック下でのがん患者のマネジメント:ESMO多職種専門職のコンセンサス(Special Articles)
Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31(10):1320-35. [PMID: 32745693]
22. 肺がん患者でのCovid-19併存の影響と重症化の関連要因
Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;31(10):1386-96. [PMID: 32561401]
23. 化学療法に伴う悪心・嘔吐に対する医療用大麻THC・CBDの無作為化比較試験
Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553-60. [PMID: 32801017]

【Eur J Cancer. 2020;136-140】
24. EORTC QLQ-C30のドイツでの国民標準値
Nolte S, Waldmann A, Liegl G, Petersen MA, Groenvold M, Rose M, et al. Updated EORTC QLQ-C30 general population norm data for Germany. Eur J Cancer. 2020;137:161-70. [PMID: 32777715]
25. Covid-19を併存したがん患者の予後:システマティックレビュー
Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50. [PMID: 32971510]
26. Covid-19を併存したがん患者の予後の多施設観察研究
Elkrief A, Desilets A, Papneja N, Cvetkovic L, Groleau C, Lakehal YA, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study. Eur J Cancer. 2020;139:181-7. [PMID: 33035991]

【Br J Cancer. 2020;123(5-11)】
27. 乳がん検診受診者を対象としたWebベースの意思決定支援の無作為化比較試験
Roberto A, Colombo C, Candiani G, Satolli R, Giordano L, Jaramillo L, et al. A dynamic web-based decision aid to improve informed choice in organised breast cancer screening. A pragmatic randomised trial in Italy. Br J Cancer. 2020;123(5):714-21. [PMID: 32546834]
28. がん診断時の併存疾患と処方薬
Loeppenthin K, Dalton SO, Johansen C, Andersen E, Christensen MB, Pappot H, et al. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication. Br J Cancer. 2020;123(6):1033-40. [PMID: 32632149]

【Cancer. 2020;126(17-22)】
29. TP53生殖細胞系列病的バリアント保持者でのがん検診と心理的苦痛
Rippinger N, Fischer C, Haun MW, Rhiem K, Grill S, Kiechle M, et al. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer. 2020;126(17):4032-41. [PMID: 32557628]
30. 頭頚部がん治療後の経済的負担の評価尺度 Financial Index of Toxicityの妥当性
Hueniken K, Douglas CM, Jethwa AR, Mirshams M, Eng L, Hope A, et al. Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire. Cancer. 2020;126(17):4042-50. [PMID: 32603521]
31. ホルモン受容体陽性乳がん患者の身体活動、QOL、補助ホルモン療法関連症状
Sheppard VB, Dash C, Nomura S, Sutton AL, Franco RL, Lucas A, et al. Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer. Cancer. 2020;126(17):4059-66. [PMID: 32614992]
32. 転移性乳がん患者の年齢と生産性減少
Trogdon JG, Liu X, Reeder-Hayes KE, Rotter J, Ekwueme DU, Wheeler SB. Productivity costs associated with metastatic breast cancer in younger, midlife, and older women. Cancer. 2020. [PMID: 32648979]
33. がん関連認知機能障害に対するマインドフルネス介入の効果
Van der Gucht K, Ahmadoun S, Melis M, de Cloe E, Sleurs C, Radwan A, et al. Effects of a mindfulness-based intervention on cancer-related cognitive impairment: Results of a randomized controlled functional magnetic resonance imaging pilot study. Cancer. 2020. [PMID: 32639592]
34. 非小細胞肺がん患者の脳転移診断時の認知機能症状と予後との関連
Steindl A, Yadavalli S, Gruber KA, Seiwald M, Gatterbauer B, Dieckmann K, et al. Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases. Cancer. 2020;126(19):4341-52. [PMID: 32678971]
35. 米国の2001〜2016 年の小児がんの予後
Siegel DA, Richardson LC, Henley SJ, Wilson RJ, Dowling NF, Weir HK, et al. Pediatric cancer mortality and survival in the United States, 2001-2016. Cancer. 2020;126(19):4379-89. [PMID: 32725630]
36. AYA世代がん患者の就学・就業・経済への影響
Sisk BA, Fasciano K, Block SD, Mack JW. Impact of cancer on school, work, and financial independence among adolescents and young adults. Cancer. 2020;126(19):4400-6. [PMID: 32658324]
37. 卵巣がん患者の上皮間葉転換と社会的孤立の関連
Lutgendorf SK, Penedo F, Goodheart MJ, Dahmoush L, Arevalo JMG, Thaker PH, et al. Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. Cancer. 2020;126(19):4407-13. [PMID: 32691853]
38. AYA世代がん治療へのCovid-19の影響
Kosir U, Loades M, Wild J, Wiedemann M, Krajnc A, Roskar S, et al. The impact of COVID-19 on the cancer care of adolescents and young adults and their well-being: Results from an online survey conducted in the early stages of the pandemic. Cancer. 2020;126(19):4414-22. [PMID: 32697342]
39. がん治療に続発する粘膜炎管理:MASCC/ISOO臨床診療ガイドライン
Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423-31. [PMID: 32786044]
40. 消化器がんでのリソースの地域差とがん治療へのアクセス
Davis LE, Coburn NG, Hallet J, Earle CC, Liu Y, Myrehaug S, et al. Material deprivation and access to cancer care in a universal health care system. Cancer. 2020;126(20):4545-52. [PMID: 32745271]
41. カナダでのAYA世代のがん罹患の傾向
Heer EV, Harper AS, Sung H, Jemal A, Fidler-Benaoudia MM. Emerging cancer incidence trends in Canada: The growing burden of young adult cancers. Cancer. 2020;126(20):4553-62. [PMID: 32770762]
42. がん予防の知識とがん罹患リスクの中国でのコホート研究
Li H, Zeng H, Zheng R, Zou X, Cao M, Sun D, et al. Association of cancer awareness levels with the risk of cancer in rural China: A population-based cohort study. Cancer. 2020;126(20):4563-71. [PMID: 32780477]
43. 社会的弱者向けの病院でのがん医療の質
Sarkar RR, Courtney PT, Bachand K, Sheridan PE, Riviere PJ, Guss ZD, et al. Quality of care at safety-net hospitals and the impact on pay-for-performance reimbursement. Cancer. 2020;126(20):4584-92. [PMID: 32780469]
44. がん患者の家族介護者 unmet needsの8年間のコホート研究
Kim Y, Carver CS, Ting A, Cannady RS. Passages of cancer caregivers' unmet needs across 8 years. Cancer. 2020;126(20):4593-601. [PMID: 32770755]
45. 化学療法関連神経障害疼痛の研究デザイン
St Germain DC, O'Mara AM, Robinson JL, Torres AD, Minasian LM. Chemotherapy-induced peripheral neuropathy: Identifying the research gaps and associated changes to clinical trial design. Cancer. 2020;126(20):4602-13. [PMID: 32780430]
46. 親の学歴と子のがん死亡率との関連
Alicandro G, Bertuccio P, Sebastiani G, La Vecchia C, Frova L. Parental education and cancer mortality in children, adolescents, and young adults: A case-cohort study within the 2011 Italian census cohort. Cancer. 2020;126(21):4753-60. [PMID: 32809229]
47. 低所得患者でのがん診断後の慢性疾患の処方アドヒアランスや治療の変化
Spees LP, Wheeler SB, Zhou X, Amin KB, Baggett CD, Lund JL, et al. Changes in chronic medication adherence, costs, and health care use after a cancer diagnosis among low-income patients and the role of patient-centered medical homes. Cancer. 2020;126(21):4770-9. [PMID: 32780539]
48. 人種とがん治療開始の遅れとの関連
Emerson MA, Golightly YM, Aiello AE, Reeder-Hayes KE, Tan X, Maduekwe U, et al. Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women. Cancer. 2020;126(22):4957-66. [PMID: 32954493]
49. p16INK4a遺伝子発現とAYA世代がん患者の老化との関連
Smitherman AB, Wood WA, Mitin N, Ayer Miller VL, Deal AM, Davis IJ, et al. Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16(INK4a) and frailty. Cancer. 2020;126(22):4975-83. [PMID: 32830315]
50.ユーラシア11か国での小児がん患者への早期緩和ケア提供の障害
Ehrlich BS, Movsisyan N, Batmunkh T, Kumirova E, Borisevich MV, Kirgizov K, et al. Barriers to the early integration of palliative care in pediatric oncology in 11 Eurasian countries. Cancer. 2020;126(22):4984-93. [PMID: 32813913]

Close